Press Releases September 8, 2026 08:00 AM

Rani Therapeutics to Participate in Upcoming September Conferences

Rani Therapeutics Announces Management Participation in September Investor Conferences

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
RANI

Rani Therapeutics Holdings, a clinical-stage biotherapeutics company focused on oral delivery of biologics, announced that its management team will participate in several investment conferences in September 2026, including the BIG10 Conference and the H.C. Wainwright Global Investment Conference. The company will present its latest developments and webcast the sessions for investors.

Rani Therapeutics to Participate in Upcoming September Conferences
RANI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Rani Therapeutics is showcasing its advancements in oral biologics delivery technology through upcoming investor conferences.
  • The company plans to webcast its presentation, increasing accessibility for investors and stakeholders.
  • Participation in these conferences will likely give updates on clinical progress and business outlook for RaniPill® Capsule technology, which aims to replace injectable biologics.

SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming September conferences.

10th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital Markets
Date: Thursday, September 10, 2026
Format: 1x1 Meetings
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Fireside Chat: Monday, September 14, 2026 at 4:00pm E.T.
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas
Format: Fireside Chat and 1x1 Meetings
Location: New York, NY

Interested parties can access the live webcast for the H.C. Wainwright conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation.

About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® Capsule™, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® Capsule technology.

Investor Contact:
[email protected]

Media Contact:
[email protected]


Risks

  • As a clinical-stage biotherapeutics company, Rani Therapeutics faces typical risks related to clinical trials, including potential delays or negative results impacting product development.
  • Market acceptance of orally delivered biologics technology remains uncertain and may affect commercial viability.
  • Financial performance and investor sentiment may be influenced by the outcomes of the upcoming presentations and ongoing regulatory approvals.

More from Press Releases

Barfresh Receives USDA Re-Approval of $2.4 Million Grant Following Updated Facility Design, Equipment and Installation Requirements Sep 8, 2026 BOS to Present at Sidoti’s Small-Cap Virtual Investor Conference September 23-24, 2026 Sep 8, 2026 Trust Stamp Collaborates with Jack Henry® to Combat Sophisticated Identity Fraud with Government-Backed DMV Data Verification Sep 8, 2026 Kodiak AI On Track For Year-End Driverless Long-Haul Launch as Safety Case Readiness Reaches 93% Sep 8, 2026 T3 Defense Targets Accelerating European Demand for Air Defense Ground-System Components Sep 8, 2026